TriSalus Life Sciences Appoints New Board Members to Enhance Oncology Innovations
- TriSalus Life Sciences appointed William J. Valle and Gary B. Gordon to its Board of Directors on January 29, 2025.
- Valle's experience in medical device commercialization and Gordon’s oncology expertise will enhance TriSalus' cancer treatment innovations.
- The new board members aim to advance TriSalus' Pressure-Enabled Drug Delivery™ and Pancreatic Retrograde Venous Infusion systems.
TriSalus Life Sciences Welcomes New Board Members to Propel Oncology Innovations
TriSalus Life Sciences® Inc., a pioneering biomedical technology company dedicated to enhancing treatment outcomes for solid tumors, announces the appointment of William J. Valle and Gary B. Gordon, M.D., Ph.D., to its Board of Directors, effective January 29, 2025. This strategic move is poised to bolster the company’s efforts in revolutionizing cancer treatment through its innovative technologies. Mats Wahlstrom, Chairman of TriSalus, expresses optimism regarding their contributions, underscoring Valle’s substantial experience in medical device commercialization and Gordon’s extensive background in oncology.
Valle’s previous role as CEO of North America at Fresenius Medical Care equips him with invaluable insights into the operational intricacies of the healthcare sector, particularly in medical device commercialization and reimbursement strategies. His leadership at Fresenius, where he managed a vast network of dialysis facilities catering to approximately 187,000 patients, positions him as a vital asset for TriSalus. Valle emphasizes the transformative potential of the company’s Pressure-Enabled Drug Delivery™ (PEDD™) technology, which aims to enhance the delivery of therapeutics directly to solid tumors, addressing a critical need in cancer care.
Dr. Gordon complements Valle’s expertise with his significant contributions to oncology, having played a pivotal role in developing AbbVie’s oncology franchise and overseeing a multi-billion-dollar oncology program. He underscores the promise of the TriSalus Pancreatic Retrograde Venous Infusion (PRVI™) System, which is engineered to deliver potent therapeutics directly to pancreatic tumors, a notoriously challenging area in oncology. Gordon expresses eagerness to collaborate with Valle and the existing leadership team to integrate this innovative technology with therapies such as nelitolimod, with the ultimate goal of improving treatment outcomes for patients grappling with difficult-to-treat solid tumors.
Together, Valle and Dr. Gordon bring a wealth of experience and a strategic vision that aligns with TriSalus' commitment to transforming cancer care. Their appointments reflect the company’s focus on leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes in oncology, particularly for those with hard-to-treat solid tumors.
In addition to the board appointments, TriSalus continues to focus on advancing its innovative technologies, which stand to redefine therapeutic strategies in oncology. The collaboration between these seasoned professionals is expected to further elevate TriSalus' mission, as they work to integrate cutting-edge delivery systems with current and emerging therapies. This leadership expansion not only signifies growth for TriSalus but also strengthens its commitment to addressing the pressing challenges faced in treating solid tumors.